We invite postgraduate research proposals in a number of disease areas that impact significantly on patient care. We focus on exploring the mechanisms of disease, understanding the ways disease impacts patients’ lives, utilising new diagnostic and therapeutic techniques and developing new treatments.
As a student you will be registered with a University research institute, for many this is the Institute for Cellular Medicine (ICM). You will be supported in your studies through a structured programme of supervision and training via our Faculty of Medical Sciences Graduate School.
We undertake the following areas of research and offer MPhil, PhD and MD supervision in:
Newcastle hosts one of the most comprehensive organ transplant programmes in the world. This clinical expertise has developed in parallel with the applied immunobiology and transplantation research group. We are investigating aspects of the immunology of autoimmune diseases and cancer therapy, in addition to transplant rejection. We have themes to understand the interplay of the inflammatory and anti-inflammatory responses by a variety of pathways, and how these can be manipulated for therapeutic purposes. Further research theme focusses on primary immunodeficiency diseases.
There is strong emphasis on the integration of clinical investigation with basic science. Our research include:
We also research the effects of UVR on the skin including mitochondrial DNA damage as a UV biomarker.
This area emphasises on translational research, linking clinical- and laboratory-based science. Key research include:
Focus is on applied research and aims to underpin future clinical applications. Technology-oriented and demand-driven research is conducted which relates directly to health priority areas such as:
This research is sustained through extensive internal and external collaborations with leading UK and European academic and industrial groups, and has the ultimate goal of deploying next-generation diagnostic and therapeutic systems in the hospital and health-care environment.
There is a number of research programmes into the genetics, immunology and physiology of kidney disease and kidney transplantation. We maintain close links between basic scientists and clinicians with many translational programmes of work, from the laboratory to first-in-man and phase III clinical trials. Specific areas:
We have particular interests in:
Novel non-invasive methodologies using magnetic resonance are developed and applied to clinical research. Our research falls into two categories:
Our studies cover a broad range of topics (including diabetes, dementia, neuroscience, hepatology, cardiovascular, neuromuscular disease, metabolism, and respiratory research projects), but have a common theme of MR technical development and its application to clinical research.
We focus on connective tissue diseases in three, overlapping research programmes. These programmes aim to understand:
This research theme links with other local, national and international centres of excellence and has close integration of basic and clinical researchers and hosts the only immunotherapy centre in the UK.
Genetic approaches to the individualisation of drug therapy, including anticoagulants and anti-cancer drugs, and in the genetics of diverse non-Mendelian diseases, from diabetes to periodontal disease, are a focus. A wide range of knowledge and experience in both genetics and clinical sciences is utilised, with access to high-throughput genotyping platforms.
Our scientists and clinicians use in situ cellular technologies and large-scale gene expression profiling to study the normal and pathophysiological remodelling of vascular and uteroplacental tissues. Novel approaches to cellular interactions have been developed using a unique human tissue resource. Our research themes include:
We also have preclinical molecular biology projects in breast cancer research.
We conduct a broad range of research activities into acute and chronic lung diseases. As well as scientific studies into disease mechanisms, there is particular interest in translational medicine approaches to lung disease, studying human lung tissue and cells to explore potential for new treatments. Our current areas of research include:
Our research projects are concerned with the harmful effects of chemicals, including prescribed drugs, and finding ways to prevent and minimise these effects. We are attempting to measure the effects of fairly small amounts of chemicals, to provide ways of giving early warning of the start of harmful effects. We also study the adverse side-effects of medicines, including how conditions such as liver disease and heart disease can develop in people taking medicines for completely different medical conditions. Our current interests include: environmental chemicals and organophosphate pesticides, warfarin, psychiatric drugs and anti-cancer drugs.
Our new School of Pharmacy has scientists and clinicians working together on all aspects of pharmaceutical sciences and clinical pharmacy.
The Department of Oncology and the Department for Continuing Education’s CPD Centre offer a part-time MSc in Experimental and Translational Therapeutics that brings together some of Oxford's leading clinicians and scientists to deliver an advanced modular programme designed for those in full-time employment, both in the UK and overseas.
The Programme draws on the world-class research and teaching in experimental therapeutics at Oxford University and offers a unique opportunity to gain an understanding of the principles that underpin clinical research and to translate this into good clinical and research practice.
Visit the website https://www.conted.ox.ac.uk/about/msc-in-experimental-therapeutics
If your application is completed by this January deadline and you fulfil the eligibility criteria, you will be automatically considered for a graduate scholarship. For details see: http://www.ox.ac.uk/admissions/graduate/fees-and-funding/graduate-scholarships.
The MSc in Experimental and Translational Therapeutics is a part-time course consisting of six modules and a research project and dissertation. The programme is normally completed in two to three years. Students are full members of the University of Oxford and are matriculated as members of an Oxford college.
The modules in this programme can also be taken as individual short courses. It is possible to transfer credit from up to three previously completed modules into the MSc programme, if the time elapsed between commencement of the accredited module(s) and registration for the MSc is not more than two years.
- The Structure of Clinical Trials and Experimental Therapeutics
- Drug Development, Pharmacokinetics and Imaging
- Pharmacodynamics, Biomarkers and Personalised Therapy
- Adverse Drug Reactions, Drug Interactions, and Pharmacovigilance
- How to do Research on Therapeutic Interventions: Protocol Preparation
- Biological Therapeutics
The aim of the MSc programme is to provide students with the necessary training and practical experience to enable them to understand the principles that underpin clinical research, and to enable them to translate that understanding into good clinical and research practice.
By the end of the MSc programme, students should understand the following core principles:
- Development, marketing and regulations of drugs
- Pharmaceutical factors that affect drug therapy
- Pharmacokinetics, pharmacogenetics and pharmacodynamics
- Adverse drug reactions, drug interactions, and pharmacovigilance
- Designing phase I, II and III clinical trials for a range of novel therapeutic interventions (and imaging agents).
- Application of statistics to medicine
- Laboratory assays used to support trial end-points
- Use of non-invasive imaging in drug development
- Application of analytical techniques
By the end of the programme, students should be equipped to:
- demonstrate a knowledge of the principles, methods and techniques for solving clinical research problems and translate this into good clinical and research practice
- apply skills gained in techniques and practical experience from across the medical and biological sciences
- develop skills in managing research-based work in experimental therapeutics
- carry out an extended research project involving a literature review, problem specification and analysis in experimental therapeutics and write a short dissertation
Guidance from the UK Royal College of Physician's Faculty of Pharmaceutical Medicine
The Faculty have confirmed that if enrolled for Pharmaceutical Medicine Specialty Training (PMST), trainees may be able to use knowledge provided by Experimental Therapeutics modules to cover aspects of a module of the PMST curriculum. Trainees are advised to discuss this with their Educational Supervisor.
Experimental Therapeutics modules may also be used to provide those pursuing the Faculty's Diploma in Pharmaceutical Medicine (DPM) with the necessary knowledge required to cover the Diploma syllabus. Applicants for the DPM exam are advised to read the DPM syllabus and rules and regulations.
Members of the Faculty of Pharmaceutical Medicine who are registered in the Faculty's CPD scheme can count participation in Experimental Therapeutics modules towards their CPD record. Non-members may wish to obtain further advice about CPD credit from their Royal College or Faculty.
To complete the MSc, students need to:
Attend the six modules and complete an assessed written assignment for each module.
Complete a dissertation on a topic chosen in consultation with a supervisor and the Course Director.
The dissertation is founded on a research project that builds on material studied in the taught modules. The dissertation should normally not exceed 15,000 words.
The project will normally be supervised by an academic supervisor from the University of Oxford, and an employer-based mentor.
The following are topics of dissertations completed by previous students on the course:
- The outcomes of non-surgical management of tubal pregnancy; a 6 month study of the South East London population
- Analysis of the predictive and prognostic factors of outcome in a cohort of patients prospectively treated with perioperative chemotherapy for adenocarcinoma of the stomach or of the gastroesophageal junction
- Evolution of mineral and bone disorder in early Chronic Kidney Disease (CKD): the role of FGF23 and vitamin D
- Survey of patients' knowledge and perception of the adverse drug reporting scheme (yellow cards) in primary care
- The predictive role of ERCC1 status in oxaliplatin based Neoadjuvant for metastatic colorectal cancer (CRC) to the liver
- Endothelial Pathophysiology in Dengue - Dextran studies during acute infection
- Literature review of the use of thalidomide in cancer
- An investigation into the phenotypical and functional characteristics of mesenchymal stem cells for clinical application
- Identification of genetic variants that cause capecitabine and bevacizumab toxicity
- Bridging the evidence gap in geriatric medicines via modelling and simulations
The class-based modules will include a period of preparatory study, a week of intensive face-to-face lectures and tutorials, followed by a period for assignment work. Attendance at modules will be a requirement for study. Some non-classroom activities will be provided at laboratory facilities elsewhere in the University. The course will include taught material on research skills. A virtual learning environment (VLE) will provide between-module support.
The taught modules will include group work, discussions, guest lectures, and interaction and feedback with tutors and lecturers. Practical work aims to develop the students' knowledge and understanding of the subject.
Find out how to apply here - http://www.ox.ac.uk/admissions/graduate/applying-to-oxford
This MRes Cancer Biology course will give you advanced knowledge of cellular systems. You will learn about the pathogenesis of cancer, cardiovascular disease, diabetes and kidney fibrosis, along with an exploration of current approaches to cancer gene therapy and immunotherapy.
Visit us on campus throughout the year, find and register for our next open event on http://www.ntu.ac.uk/pgevents.
The Centre for Inflammation Research (CIR) aims to promote the prevention, diagnosis and treatment of inflammatory diseases through interdisciplinary study of the initiation, regulation and resolution of inflammatory responses and provision of an outstanding environment for research training in the field.
CIR investigators aim to characterise and manipulate key control points in inflammation. We focus on:
We have particular interest in inflammatory diseases of the lung and kidney but the principles derived will have ready application to inflammatory responses in the liver, bowel, bone/joint and skin. There is also increasing development of research in the CIR into the links between inflammation and cancer.
The Centre was formally established in 1998.
Generic training in presentation skills, project management and writing skills is delivered through the University of Edinburgh's transferable skills programme.
The CIR is a multidisciplinary team of research groups under the directorship of Professor John Iredale. The CIR consists of more than 180 researchers, is equipped with state-of-the-art apparatus and is supported by external grant funding. The CIR is now located in the purpose-built Queen's Medical Research Institute along with the centres for Reproductive Biology and Cardiovascular Sciences.
The department of Surgery is headed by Professor O James Garden and has an international profile in surgical research.
Strong research themes include liver injury and regeneration, innate immunity, the role of the macrophage in chronic kidney-graft rejection, foetal liver stem-cell research, cancer inflammation, medical imaging using microbubbles, modification of stress response pathways and aspects of clinical research in hepatobiliary surgery and transplantation.
We cater for our wide range of disciplines with extensive facilities and critical investment in order to create the perfect environment for discovery.